- Home
- ANVS vs GNLX Comparison
ANVS vs GNLX Comparison
Compare ANVS & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | GNLX |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.6M | 110.4M |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ANVS | GNLX |
|---|---|---|
| Price | $1.13 | $2.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $13.50 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 997.8K | 297.3K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.39 | 9.47 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.22 | $2.29 |
| 52 Week High | $5.50 | $8.54 |
Technical Indicators
Market Signals| Indicator | ANVS | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 22.48 | 38.62 |
| Support Level | N/A | $2.33 |
| Resistance Level | $2.02 | $2.97 |
| Average True Range (ATR) | 0.10 | 0.16 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 3.65 | 11.61 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.